In recent weeks, a new type of virus widely known as the coronavirus (sometimes called COVID-19) has been spreading around the world. There have been a number of stories in the news of people getting sick from this new virus.
Given that people with lupus are at higher risk for a number of types of infections, including viruses, it is only natural to be concerned about the coronavirus.
The Centers for Disease Control and Prevention (CDC) is closely watching the coronavirus both internationally and here in the U.S. The risk of catching the coronavirus in the U.S. is very low.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.